Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GCLLSG 2016 | Key considerations for mutation detection in CLL

Anna Schuh, MD, PhD, MRCP, FRCPath of University of Oxford, Oxford, UK, discusses mutation detection using standardized next-generation sequencing (NGS) technology. Dr Schuh mentions that NGS method should be sensitive enough to detect mutations at a level of 1-5% and include testing for strong predictors of lack of response to chemoimmunotherapy and immunoglobulin gene rearrangement. In the UK, all patients participating in a trial of ibrutinib with rituximab for chronic lymphocytic leukaemia (FLAIR) participate in the whole genome sequencing (WGS), which is a source of unbiased data on the effect of treatment on patient populations. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.